EWM Training for Attention Deficit Hyperactivity Disorder (ADHD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Attention Deficit Hyperactivity Disorder (ADHD)
EWM Training - Behavioral
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new working memory training intervention for ADHD to see if it affects the frontoparietal brain network and behavior.

Treatment Effectiveness

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Change in scores from baseline assessment versus 5 weeks at the conclusion of training

Week 5
Magnetic Resonance Imaging Functional Brain Scan using a Seimens 3T Skyra.
Week 5
The experimental executive working memory training tasks

Trial Safety

Trial Design

2 Treatment Groups

ADHD EWM
1 of 2
ADHD Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

62 Total Participants · 2 Treatment Groups

Primary Treatment: EWM Training · Has Placebo Group · N/A

ADHD EWM
Behavioral
Experimental Group · 1 Intervention: EWM Training · Intervention Types: Behavioral
ADHD Placebo
Behavioral
PlaceboComparator Group · 1 Intervention: Placebo Training · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: change in scores from baseline assessment versus 5 weeks at the conclusion of training

Who is running the clinical trial?

Hartford HospitalLead Sponsor
117 Previous Clinical Trials
16,891 Total Patients Enrolled
1 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
38 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Michael C Stevens, PhDPrincipal InvestigatorInstitute of Living/Hartford Hospital
1 Previous Clinical Trials
40 Total Patients Enrolled

Eligibility Criteria

Age < 65 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Between ages 12-18

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: November 14th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
California28.6%
North Carolina28.6%
Pennsylvania14.3%
Other28.6%
How old are they?
18 - 65100.0%
What site did they apply to?
Hartford Hospital50.0%
Institute of Living/Hartford Hospital50.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria33.3%
Met criteria66.7%

How responsive is this trial?

Typically responds via
Email100.0%